文献速递鼻科

慢性鼻窦炎药物治疗随机对照试验中的安慰剂效应:系统综述与Meta分析

The placebo effect in randomized-controlled trials of medical treatments for chronic rhinosinusitis: A systematic review and meta-analysis.
PubMed 文献 · Int Forum Allergy Rhinol · 2023-11-20

该系统综述与Meta分析纳入21项随机对照试验、共1437例慢性鼻窦炎患者,评估药物治疗中安慰剂对患者报告结局和客观指标的影响。安慰剂治疗后SNOT-22等多项患者报告结局显著改善,Lund-Mackay CT评分和鼻吸气峰流量也出现显著变化;未使用背景药物时安慰剂效应最大。作者认为需进一步研究以全面理解安慰剂效应。

要点

  • 安慰剂治疗后SNOT-22评分平均差为-9.49(95%CI -11.26至-7.73)。
  • 安慰剂使Lund-Mackay CT评分变化-0.82(95%CI -1.48至-0.16)。
  • 未使用背景药物时安慰剂效应最大。

核心结论

  • 安慰剂治疗对慢性鼻窦炎患者报告结局和部分客观结局具有统计学显著且可能临床显著的影响。
  • 需要进一步研究以全面理解安慰剂效应,这可能改善随机对照试验的评估并影响患者照护。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Scopus和CINAHL数据库。
  • 纳入评估慢性鼻窦炎药物治疗与安慰剂对比的随机对照试验。
  • 共纳入21项随机对照试验,包含1437例患者,平均年龄49.2岁。

主要发现

  • 生物制剂是最常研究的治疗(n=9),11项研究在安慰剂基础上给予背景类固醇。
  • 安慰剂后SNOT-22评分平均差为-9.49(95%CI -11.26至-7.73)。
  • 安慰剂后鼻塞评分平均差为-0.33(95%CI -0.54至-0.13),嗅觉评分平均差为-0.22(95%CI -0.33至-0.11)。
  • 安慰剂后鼻塞VAS平均差为-2.47(95%CI -2.87至-2.06),嗅觉丧失VAS平均差为-2.31(95%CI -4.14至-0.47)。
  • 安慰剂后Lund-Mackay CT评分变化为-0.82(95%CI -1.48至-0.16),鼻吸气峰流量变化为4.70(95%CI 4.76至24.64)。

关键数值与推荐

  • 患者报告结局包括SNOT-22、鼻塞、嗅觉、鼻塞VAS、嗅觉VAS、前鼻漏和鼻后滴漏。
  • 客观结局包括Lund-Mackay CT评分、鼻吸气峰流量、鼻息肉评分、40项嗅觉识别测试、血清IgE和血嗜酸性粒细胞水平。
  • 未使用背景药物时安慰剂效应最大。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步研究以全面理解安慰剂效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The placebo effect observed in clinical trials evaluating medical treatments for chronic rhinosinusitis (CRS) is not well understood. This systematic review and meta-analysis sought to characterize the placebo effect present within CRS outcomes. METHODS: A systematic review of PubMed, Scopus, and Cumulated Index in Nursing and Allied Health Nursing (CINAHL) was performed. Randomized controlled trials (RCTs) evaluating medical treatments for CRS versus placebo were included. We assessed patient-reported (sino-nasal outcome test 22 [SNOT-22], nasal obstruction, sense of smell, nasal obstruction visual analogue score [VAS], sense of smell VAS, anterior rhinorrhea, and postnasal drip) and objective (Lund-Mackay Computed tomography (CT) score, peak nasal inspiratory flow [PNIF], nasal polyp scores, 40-item Smell Identification Test, serum IgE, and blood eosinophil levels) outcomes. RESULTS: Twenty-one RCTs were included, comprising 1437 patients (mean age 49.2 years). Biologics were the most common treatment investigated (n = 9). Eleven studies administered background steroids along with placebo. Following placebo administration, multiple patient-reported outcomes significantly decreased, including SNOT-22 (mean difference -9.49, 95% confidence interval [CI] [-11.26, -7.73]), nasal obstruction (-0.33 [-0.54, -0.13]), sense of smell (-0.22 [-0.33, -0.11]), nasal obstruction VAS (-2.47 [-2.87, -2.06]), and loss of smell VAS (-2.31 [-4.14, -0.47]) scores. For objective measures, significant changes occurred in Lund-Mackay CT score (-0.82, [-1.48, -0.16]) and PNIF (4.70, [4.76, 24.64]) with placebo. Placebo arms had the greatest impact when no background medications were used. CONCLUSIONS: Placebo treatments have a statistically and potentially clinically significant effect on patient-reported and some objective CRS outcomes. Further investigation is required to fully understand placebo effect, which could improve assessment of RCTs and impact patient care.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Pipaliya RM, Duckett KA, Monaghan NP, et al. The placebo effect in randomized-controlled trials of medical treatments for chronic rhinosinusitis: A systematic review and meta-analysis. Int Forum Allergy Rhinol. 2023. PMID: 37985206. doi:10.1002/alr.23302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。